Rigel Pharmaceuticals | RIGL - Interest Expense On Debt


Rigel Pharmaceuticals reported $2.06M in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
Agenus USD 14.67M 1.35M Mar/2026
Amgen USD 95.64B 94.98B Jun/2026
Anika Therapeutics 183.47M 4.09M Jun/2026
Arrowhead Research USD 24.56M 716K Jun/2026
AstraZeneca USD 340M 144M Jun/2026
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Daiichi Sankyo JPY 3.57B 1.4B Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Heron Therapeutics USD 600K 100K Dec/2024
Intrexon USD 2K 5K Jun/2024
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
MacroGenics USD 4.89M 1.55M Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pfizer USD 667M 4M Jun/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Veracyte USD 2K 1000 Dec/2023